OptimizeRx Corp. (OPRX) Q4 Earnings and Revenues Beat Estimates

Company Performance - OptimizeRx Corp. reported quarterly earnings of $0.30 per share, exceeding the Zacks Consensus Estimate of$ 0.25 per share, and up from $0.26 per share a year ago, representing an earnings surprise of 20% [1] - The company posted revenues of$ 32.32 million for the quarter ended December 2024, surpassing the Zacks Consensus Estimate by 9.58%, compared to year-ago revenues of $28.37 million [2] - Over the last four quarters, OptimizeRx has surpassed consensus EPS estimates three times and topped consensus revenue estimates two times [2] Stock Outlook - The stock has underperformed, losing about 14.8% since the beginning of the year, while the S&P 500 declined by 5.3% [3] - The current consensus EPS estimate for the coming quarter is -$ 0.05 on revenues of $21.28 million, and for the current fiscal year, it is$ 0.35 on revenues of $101.3 million [7] - The estimate revisions trend for OptimizeRx is mixed, resulting in a Zacks Rank 3 (Hold), indicating expected performance in line with the market in the near future [6] Industry Context - The Computer - Software industry, to which OptimizeRx belongs, is currently in the top 29% of over 250 Zacks industries, suggesting a favorable outlook [8] - Empirical research indicates a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can be tracked by investors [5]